Patients with advanced biliary tract cancers might benefit from first-line pembrolizumab combined with chemotherapy.

Published Date: 19 Apr 2023

Results from the phase III KEYNOTE-966 study showed that adding pembrolizumab (Keytruda) to gemcitabine and cisplatin increased overall survival in patients with untreated metastatic or unresectable biliary tract cancer.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot